-+ 0.00%
-+ 0.00%
-+ 0.00%

DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS THE FIRST NEW TARGETED THERAPY IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA (CSU)

Reuters·04/18/2025 15:17:20

Please log in to view news